AstraZeneca's Etcamah Gets FDA Nod, Revolutionizing Advanced Breast Cancer Treatment
In a significant leap for cancer care, the U.S. Food and Drug Administration (FDA) has granted accelerated approval to AstraZeneca's Etcamah (camizestrant) in combination with a CDK 4/6 inhibitor for patients with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer featuring an ESR1 mutation. This approval marks a pivotal shift, allowing doctors to intervene earlier based on a simple blood test, rather than waiting for tumors to visibly grow on scans. The decision comes even after an advisory committee's earlier concerns regarding the trial's reliance on liquid biopsies.











